Hodgkin Lymphoma News

Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma - CancerNetwork

Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma CancerNetwork

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma - Nature

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma Nature

U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings - AboutLawsuits.com

U.S. Supreme Court Blocks Roundup Lawsuits Over Non-Hodgkin’s Lymphoma Warnings AboutLawsuits.com

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights

Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights

Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom

Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom

Post-Treatment Fertility in Hodgkin Lymphoma - Hematology Advisor

Post-Treatment Fertility in Hodgkin Lymphoma Hematology Advisor

What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? - Reuters

What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits? Reuters

Bayer scores landmark victory as Supreme Court overturns Roundup verdict - Fierce Pharma

Bayer scores landmark victory as Supreme Court overturns Roundup verdict Fierce Pharma

Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma - Clemson University Athletics

Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma Clemson University Athletics

Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity - Cureus

Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity Cureus

Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma - CancerNetwork

Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma CancerNetwork

FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology

FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia - Nature

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia Nature

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist - Hematology Advisor

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist Hematology Advisor

BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma - CancerNetwork

BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma CancerNetwork

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma - CancerNetwork

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma CancerNetwork

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study - Nature

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature

AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma - CancerNetwork

AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma CancerNetwork

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork

Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork

Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork

Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive

FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive

Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress

Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress

Advances in lymphoma treatment therapies and clinical trials - Penn Medicine

Advances in lymphoma treatment therapies and clinical trials Penn Medicine

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers

Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report - Frontiers

Richter transformation to classical Hodgkin lymphoma following recurrent disseminated histoplasmosis in chronic lymphocytic leukemia: a Case Report Frontiers

Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ - Fred Hutchinson Cancer Center

Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ Fred Hutchinson Cancer Center